|
WO1998041229A1
(en)
*
|
1997-03-19 |
1998-09-24 |
F. Hoffmann-La Roche Ag |
USE OF IL-12p40 AS IMMUNOSTIMULANT
|
|
JP4336452B2
(ja)
|
1997-12-08 |
2009-09-30 |
メルク パテント ゲーエムベーハー |
標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
MXPA00010070A
(es)
*
|
1998-04-15 |
2004-03-10 |
Lexigen Pharm Corp |
Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
|
|
JP2002524530A
(ja)
*
|
1998-09-15 |
2002-08-06 |
ジェネティックス・インスチチュート・インコーポレーテッド |
Ｉｌ−１２を用いるカポジ肉腫の治療
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
EP1200479B1
(en)
*
|
1999-08-09 |
2006-02-01 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
US20030190305A1
(en)
*
|
1999-09-15 |
2003-10-09 |
Wyeth And National Institutes Of Health |
Treatment of Kaposi's sarcoma with IL-12
|
|
WO2001026717A1
(en)
|
1999-10-11 |
2001-04-19 |
Needleless Ventures, Inc. |
Universal anti-infectious protector for needleless injectors
|
|
US7074210B2
(en)
*
|
1999-10-11 |
2006-07-11 |
Felton International, Inc. |
Universal protector cap with auto-disable features for needle-free injectors
|
|
EP1142590B8
(en)
*
|
1999-10-29 |
2008-11-26 |
AnGes MG, Inc. |
Gene therapy for diabetic ischemic disease
|
|
WO2001036489A2
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
|
US7887506B1
(en)
|
1999-11-23 |
2011-02-15 |
Pulse Needlefree Systems, Inc. |
Safety mechanism to prevent accidental patient injection and methods of same
|
|
US6770054B1
(en)
|
1999-11-23 |
2004-08-03 |
Felton International, Inc. |
Injector assembly with driving means and locking means
|
|
US7115712B1
(en)
|
1999-12-02 |
2006-10-03 |
Maxygen, Inc. |
Cytokine polypeptides
|
|
HUP0204475A2
(en)
*
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US20020120228A1
(en)
*
|
2000-06-08 |
2002-08-29 |
Yuh-Fun Maa |
Powder compositions
|
|
US20040213798A1
(en)
*
|
2000-06-08 |
2004-10-28 |
Powderject Vaccines, Inc. |
Spray-dried alum compositions
|
|
CA2412845C
(en)
*
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
US20020086036A1
(en)
*
|
2000-12-05 |
2002-07-04 |
Allergan Sales, Inc. |
Methods for treating hyperhidrosis
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
HUP0303428A2
(hu)
*
|
2001-03-07 |
2004-01-28 |
Merck Patent Gmbh. |
Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
|
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
CA2349506C
(en)
*
|
2001-06-14 |
2009-12-08 |
Duke University |
A method for selective expression of therapeutic genes by hyperthermia
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
RU2366664C2
(ru)
*
|
2002-12-17 |
2009-09-10 |
Мерк Патент Гмбх |
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
|
|
CA2552590A1
(en)
*
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
EA015338B1
(ru)
|
2005-12-30 |
2011-06-30 |
Мерк Патент Гмбх |
ВАРИАНТЫ ИЛ-12p40 С УЛУЧШЕННОЙ СТАБИЛЬНОСТЬЮ
|
|
WO2007084364A2
(en)
*
|
2006-01-13 |
2007-07-26 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Improved il-12 for expression in mammalian cells
|
|
ES2636460T3
(es)
*
|
2007-10-08 |
2017-10-05 |
Intrexon Corporation |
Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer
|
|
BRPI0920679A2
(pt)
|
2008-10-08 |
2022-05-17 |
Intrexon Corp |
Células construídas expressando múltiplos imunomoduladores e usos das mesmas
|
|
AU2010241864B2
(en)
*
|
2009-04-30 |
2014-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
|
WO2010147971A2
(en)
*
|
2009-06-15 |
2010-12-23 |
New York University |
Il23 modified viral vector for recombinant vaccines and tumor treatment
|
|
CN109195621A
(zh)
|
2016-05-18 |
2019-01-11 |
莫得纳特斯公司 |
编码白细胞介素12(il12)的多核苷酸及其用途
|
|
EP3625246A1
(en)
|
2017-05-18 |
2020-03-25 |
ModernaTX, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|